Cite
PET ORIENTED INTENSIFICATION AND MAINTENANCE WITH RITUXIMAB IN FIRST LINE NON‐HODGKIN LARGE B CELL LYMPHOMA (DLBCL)
MLA
L. Mettivier, et al. “Pet Oriented Intensification and Maintenance with Rituximab in First Line Non‐Hodgkin Large B Cell Lymphoma (Dlbcl).” Hematological Oncology, vol. 39, June 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ef9d7a2302e02284b0f46a9fd50d9116&authtype=sso&custid=ns315887.
APA
L. Mettivier, G. Cassiordor, L Pezzullo, R. Guariglia, C. Martorelli, S. Luponio, R Fontana, Bianca Serio, I Ferrara, Carmine Selleri, & R Rosamilio. (2021). Pet Oriented Intensification and Maintenance with Rituximab in First Line Non‐Hodgkin Large B Cell Lymphoma (Dlbcl). Hematological Oncology, 39.
Chicago
L. Mettivier, G. Cassiordor, L Pezzullo, R. Guariglia, C. Martorelli, S. Luponio, R Fontana, et al. 2021. “Pet Oriented Intensification and Maintenance with Rituximab in First Line Non‐Hodgkin Large B Cell Lymphoma (Dlbcl).” Hematological Oncology 39 (June). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........ef9d7a2302e02284b0f46a9fd50d9116&authtype=sso&custid=ns315887.